> Details

Khatun, Mousumi; Kumar, Krishna; Baidya, Ayana; Mondal, Rajiv Kumar; Baszczyňski, Ondřej; Kalčic, Filip; Banerjee, Soma; Dhali, Gopal Krishna; Das, Kausik; Chowdhury, Abhijit; Janeba, Zlatko; Chakrabarti, Saikat; Datta, Simanti

Variability in the Responses of Hepatitis B Virus D-Subgenotypes to Antiviral Therapy: Designing Pan-D-Subgenotypic Reverse Transcriptase Inhibitors

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Variability in the Responses of Hepatitis B Virus D-Subgenotypes to Antiviral Therapy: Designing Pan-D-Subgenotypic Reverse Transcriptase Inhibitors
  • Contributor: Khatun, Mousumi; Kumar, Krishna; Baidya, Ayana; Mondal, Rajiv Kumar; Baszczyňski, Ondřej; Kalčic, Filip; Banerjee, Soma; Dhali, Gopal Krishna; Das, Kausik; Chowdhury, Abhijit; Janeba, Zlatko; Chakrabarti, Saikat; Datta, Simanti
  • imprint: American Society for Microbiology, 2022
  • Published in: Journal of Virology
  • Language: English
  • DOI: 10.1128/jvi.01800-21
  • ISSN: 0022-538X; 1098-5514
  • Origination:
  • Footnote:
  • Description: <jats:p>Current treatment of chronic hepatitis B relies heavily on nucleotide/nucleoside analogs in particular, tenofovir disoproxil fumarate (TDF) and entecavir (ETV) to keep HBV replication under control and prevent end-stage liver diseases. However, it was unclear whether the therapeutic effects of TDF/ETV differ among patients infected with different HBV genotypes and subgenotypes.</jats:p>
  • Access State: Open Access